Introduction
============

In the last decades, several new pharmaceutically active peptides and proteins have been developed as a consequence of the progress of biotechnological techniques and genetic engineering. These new therapeutic biomolecules are usually characterized by a large size, short plasma half-life, high elimination rate (easy to be degraded by enzymatic and body fluids), limited ability to cross cell membranes, and poor bioavailability through intestinal administration. Therefore, frequent injection of drug over a long therapeutic period, are generally required when such biomolecules are used for therapeutic purposes ([@b44-ijn-2-595]).

Traditional administration routes for these drugs are the oral and parenteral administration. The orally administered drug is absorbed from the gut and enters the blood stream, diffuses from the enteral absorption sites to blood and tissue, whereas a parenterally administered drug is injected directly into the blood, which is typically only possible in form of a drug solution or emulsion. After administration, the drug will be present as molecules in solution (ie, blood). It distributes in the body according to its physicochemical properties, eg, its partitioning coefficient. The presence as molecular solution turns these molecules easily accessible to degrading factors (eg, water, enzymes), and then they cannot be directed (targeted) to their desired site of action. One approach to overcome these problems would be the entrapment of those drugs into a particulate carrier system. Incorporation will protect them against degradation in vitro and in vivo, the release rate can be modified, offering as well targeting approaches. Examples of such particulate carrier systems are the polymeric nanoparticles ([@b102-ijn-2-595]; [@b54-ijn-2-595]; [@b61-ijn-2-595]; [@b21-ijn-2-595]; [@b58-ijn-2-595]), microemulsions ([@b9-ijn-2-595]), liposomes ([@b9-ijn-2-595]), solid lipid nanoparticles (SLN) ([@b65-ijn-2-595]; [@b1-ijn-2-595]; [@b31-ijn-2-595]; [@b74-ijn-2-595], [@b75-ijn-2-595]; [@b113-ijn-2-595]; [@b40-ijn-2-595]; [@b15-ijn-2-595]; [@b44-ijn-2-595]; [@b29-ijn-2-595]; [@b29-ijn-2-595]; [@b93-ijn-2-595]; [@b87-ijn-2-595]; [@b99-ijn-2-595]; [@b111-ijn-2-595]; [@b126-ijn-2-595]), nanostructured lipid carriers (NLC) ([@b74-ijn-2-595]; [@b29-ijn-2-595]; [@b29-ijn-2-595]) and self-emulsified drug delivery systems (SEDDS) ([@b42-ijn-2-595]; [@b90-ijn-2-595]; [@b128-ijn-2-595]). Despite being a very smart idea, examples of such concept never reached the pharmaceutical market. It has been tried with polymeric nanoparticles, nevertheless, reasons for this are the regulatory issues and the scaling up problems. In fact, polymers used (eg, polylactic acid (PLA) and its co-polymer with glycolic acid (PLGA) ([@b58-ijn-2-595])) are accepted by the regulatory authorities for parenteral administration as implants (eg, Zoladex^®^) and microparticles (eg, Decapeptyl^®^, Parlodel LA^®^, Enantone Depot^®^), but not in the nanoparticulate form. In contrast to microparticles, the nanoparticles can be internalized (phagocytosed) by cells, intracellular degradation can cause cytotoxic effects. In addition, there is a lack of large scale production methods ([@b70-ijn-2-595]).

Various approaches have been examined to overcome the delivery problems of peptides and proteins by means of colloidal carriers. The use of the above-mentioned lipid-based carrier systems seems to be promising.

Microemulsions are thermodynamically stable isotropic dispersions, transparent, of low viscosity, consisting of oil and water stabilized by an interfacial film of surfactant molecules, typically in conjunction with a co-surfactant. Usually, the inner phase either oil (o/w emulsions) or water (w/o emulsions) has sizes ranging from 5 to 100 nm. Microemulsions (o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides. Hydrophilic drugs of this kind can be successfully incorporated into the dispersed aqueous phase of w/o microemulsion droplets where it affords some protection against enzymatic degradation when administered orally. Sandimmune Neoral^®^, an example of a marketed formulation, is a microemulsion pre-concentrate containing a surfactant, lipophilic and hydrophilic solvents and ethanol. The presence of a surfactant and in some case a co-surfactant, and medium chain diacylglycerols is related in many cases, to the increase of membrane permeability, thereby increasing the drug uptake. Recently, considerable dosage form development activity has focused on the formulation of lecithin-based microemulsions. Lecithin is a naturally occurring, non-toxic and safe material. It is also a biological surfactant and a major component of membrane lipids ([@b18-ijn-2-595]).

Lipid nanoemulsions are fine o/w dispersions, having droplets covering the size range between 50 and 200 nm. Nanoemulsions are also referred as mini-emulsions ([@b12-ijn-2-595]). Nanoemulsions were introduced during the 50ies for the purpose of parenteral nutrition. Fatty vegetable oils (eg, soy oil) or middle chain triacylglycerols are used as lipid phase, being typically 10%--20% of the emulsion. Further ingredients include phospholipids (stabilizers, 0.6%--1.5%) and glycerol (osmolarity regulation, 2.25%). During recent years it has been recognized that these systems might also be used as drug carriers for lipophilic drugs and several formulations are nowadays commercialized. Examples include etomidate (Etomidat-Lipuro^®^) and diazepam (Diazepam-Lipuro^®^). In comparison to previous solubilization-based formulations of these drugs, a reduction of the local and systemic side effects (eg, pain during injection) has been found. The hemolytic activity of sodium oleate is decreased in lipid emulsions because the lytic agent is restricted at the interface and in the lipophilic core, and thus the direct contact with erythrocyte membranes is hindered ([@b52-ijn-2-595]). However, an important drawback related to nanoemulsions is the limited controlled release properties, due to the small size and the liquid state of the carrier. For most drugs, a rapid release will be observed. It has been estimated, that retarded drug release requires very lipophilic drugs, ie, the K~o/w~ should be larger than 10^6^:1. Advantages of nanoemulsions include toxicological safety and a high content of the lipid phase, as well as the possibility of large scale production by high pressure homogenization ([@b63-ijn-2-595]).

Peptides and proteins associated to microemulsions and nanonoemulsions are, for example, cyclosporine A ([@b90-ijn-2-595]), immunoglobulin G ([@b34-ijn-2-595]; [@b25-ijn-2-595]), insulin ([@b117-ijn-2-595]; [@b118-ijn-2-595]; [@b18-ijn-2-595], 2006), α-lactalbumin ([@b91-ijn-2-595]; [@b25-ijn-2-595]) and fusion protein vaccine ([@b33-ijn-2-595]).

Particular examples of nanoemulsions are the SEDDS, defined as isotropic mixtures of an oil, surfactant, co-surfactant and drug ([@b19-ijn-2-595]; [@b42-ijn-2-595]). These components form fine o/w nanoemulsions when introduced into aqueous media under mild agitation. The digestive motility of the stomach and intestine provides the agitation required for self-emulsification in vivo. Factors controlling the in vivo performance of SEDDS include their ability to form small droplets of oil and the polarity of the oil droplets to promote faster drug release into the aqueous phase. The smaller oil droplets provide a large interfacial area for pancreatic lipase to hydrolyze triacylglycerols and thereby to promote the rapid release of the drug and/or formation of mixed micelles of the bile salts containing the drug. The surfactants used in these formulations are known to improve the bioavailability by various mechanisms including: (i) improved drug dissolution ([@b19-ijn-2-595]), (ii) increased intestinal epithelial permeability ([@b103-ijn-2-595]), (iii) increased tight junction permeability ([@b57-ijn-2-595]), and (iv) decreased/inhibited P-glycoprotein drug efflux ([@b124-ijn-2-595]). A marketed formulation of cyclosporine (Sandimmune Neoral^®^), a micro-emulsion pre-concentrate with self-emulsifying properties, is reported to improve oral bioavailability and reduce inter- and intra-subject variability in cyclosporine pharmacokinetics. A few other studies have reported enhancement in the bioavail-ability of poorly soluble drugs when formulated as SEDDS ([@b53-ijn-2-595]; [@b42-ijn-2-595]). Since a relatively high concentration of surfactants is generally employed in the SEDDS formulation, toxicity of the surfactant being used should be taken into account. In fact, a compromise must be reached between the toxicity and self-emulsification ability of the surfactant that is considered for use. Currently, several formulations have been developed to produce modified emulsified formulations as alternative to conventional SEDDS. These include, for example, self-microemulsion formulations ([@b115-ijn-2-595]), surfactant dispersions ([@b7-ijn-2-595]), pre-formulated freeze-dried emulsions ([@b112-ijn-2-595]), microencapsulated emulsions ([@b51-ijn-2-595]), lipid/cross-linked polymeric matrices ([@b11-ijn-2-595]), self-emulsifiable pellets ([@b83-ijn-2-595]), and solid self-emulsifying systems (self-emulsifying tablets) ([@b6-ijn-2-595]). SEDDS typically produce emulsions with a droplet size between 100 and 300 nm, while self-microemulsifying drug delivery system (SMEDDS) form transparent microemulsions with a droplet size of less than 50 nm. When compared to emulsions, which are sensitive and metastable dispersed forms, SEDDS are physically stable formulations that are easy to manufacture. Thus, for lipophilic drug compounds that exhibit a dissolution rate limited absorption, these systems may offer an improvement in the rate and extent of absorption and result in more reproducible blood/time profiles ([@b42-ijn-2-595]). In order to produce peptides- or proteins-loaded SEDDS, these bioactives are first formulated in a w/o microemulsion pre-concentrate, and then dispersed into an aqueous phase to form a w/o/w microemulsion prior to administration ([@b128-ijn-2-595]). The few commercial products related to these formulations are actually nonaqueous microemulsions, also known as microemulsion pre-concentrate, where the polar solvent is ethanol and not water. Upon contact with aqueous media, such as gastrointestinal fluids, the nonaqueous microemulsion spontaneously forms a fine dispersion or aqueous microemulsion ([@b90-ijn-2-595]). Examples of peptides and proteins associated to SEDDS intended for oral administration are the cyclosporine A ([@b42-ijn-2-595]; [@b90-ijn-2-595]) and leuprolide ([@b128-ijn-2-595]).

Liposomes are spherical vesicles composed of one or more phospholipid bilayers (in most cases phosphatidylcholine). Lipophilic drugs can be incorporated within the lipid bilayers while hydrophilic drugs are solubilized in the inner aqueous core ([@b39-ijn-2-595]). Drug release, in vivo stability, and biodistribution, are determined by the size of the vesicles, their surface charge, surface hydrophobicity, and membrane fluidity ([@b96-ijn-2-595]). Membrane permeability can be adapted by the selection of the phospholipids composition, and by the presence of additives, such as cholesterol molecules. It is possible to avoid a rapid reticuloendothelial uptake of the liposomes by the incorporation of natural compounds (eg, ganglio-sides) or by the use of chemical modified polyethylene glycols (PEG's) ([@b28-ijn-2-595]). The development of such sterically stabilized systems ('stealth liposomes') allows the development of drug targeting strategies (eg, by incorporation of specific antibodies) ([@b60-ijn-2-595]). Liposomes also allow the intravenous injection of lipophilic drugs with very low water solubility, eg, amphotericin B (AmBisome^®^) ([@b47-ijn-2-595]), reducing therefore the toxicity of such drugs. However, chemical and physical stability problems have been described leading to liposome aggregation and drug degradation during storage, compromising therefore the performance of liposome as intravenous drug carriers ([@b20-ijn-2-595]; [@b63-ijn-2-595]).

Nanoparticles based on solid lipids (SLN, NLC) have been proposed as an alternative colloidal drug delivery system to polymeric nanoparticles, emulsions and liposomes ([@b71-ijn-2-595]; [@b71-ijn-2-595]). They are composed of solid lipids stabilized with an emulsifying layer in an aqueous dispersion, ie, they resemble the nanoemulsions by replacing the inner liquid lipid with a solid lipid. The use of solid lipids instead of oils is a very attractive idea to achieve controlled drug release, because drug mobility in a solid lipid should be considerably lower compared with an oily phase. SLN are composed of solid lipids and show a submicron colloidal size between 50 and 1000 ([@b67-ijn-2-595]; [@b67-ijn-2-595]). Advantages of such carriers include the composition (physiological compounds), the fast and effective production process, including the possibility of large scale production, the avoidance of organic solvents in the production procedures, and the possibility to produce high concentrated lipid suspensions. Disadvantages include low drug loading capacities (the drug loading capacity of conventional SLN is limited because of the formation of a perfect lipid crystal matrix) ([@b119-ijn-2-595]), the presence of alternative colloidal structures (micelles, liposomes, mixed micelles, drug nanocrystals) in the aqueous dispersion, the complexity of the physical state of the lipid (transformation between different modifications, possibility of supercooled melts) which cause stability problems during storage or administration (eg, gelation, particle size increase, drug expulsion). Sample dilution or water removal might significantly change the equilibrium between the different colloidal species and the physical state of the lipid ([@b63-ijn-2-595]). The solid core contains drug dissolved or dispersed in the high melting fat solid matrix. The hydrophobic chains of phospholipids are embedded in the fat matrix. Depending on the type and concentration of the lipid, 0.5 to 5% emulsifier (surfactant) is added for the physical stabilization of the system ([@b63-ijn-2-595]). In particular, poloxamer 188, polysorbate 80, lecithin, polyglycerol methylgluco distearate, sodium cocoamphoacetate or saccharose fatty acid esters are very often employed.

The second generation of lipid nanoparticles has been introduced with the NLC ([@b58-ijn-2-595]; [@b66-ijn-2-595]). These particles are prepared not from solid lipids only but from a blend of a solid lipid with a liquid lipid (oils) in such a proportion that the mixture needs to be solid at least at 40 ºC. Advantages of this delivery system are the accommodation of higher amounts of drugs due to the formation of a less ordered lipid matrix with many imperfections ([@b74-ijn-2-595], [@b75-ijn-2-595], [@b76-ijn-2-595]; [@b81-ijn-2-595]). The lipid matrix gives more flexibility for modulation of drug release, increasing the drug loading and preventing its leakage.

Similarly to polymeric nanoparticles, the solid matrix of SLN and NLC protects the incorporated drugs against chemical degradation, allowing the modulation of release profiles. Lipid nanoparticles have been tested for several administration routes ([@b63-ijn-2-595]), such as oral and peroral ([@b122-ijn-2-595]), pulmonary, ocular ([@b70-ijn-2-595]), topical, dermal and transdermal administration ([@b100-ijn-2-595], [@b101-ijn-2-595]), as well as for gene therapy ([@b104-ijn-2-595]), as new adjuvants for vaccines ([@b85-ijn-2-595]), and for parenteral delivery. Lipid nanoparticles of suitable composition have been shown to be well tolerated in vitro, as well as after bolus injection into mice and rats ([@b84-ijn-2-595]). Nanoparticles can accumulate in target tissues based on their natural host cell tropisms and on their biophysical properties (passive targeting). In practice, active targeting to cells other than the mononuclear phagocytic system (MPS) cells is often insufficient for rapid and specific accumulation in target tissues. Further improvement of tissue selectivity can be achieved by engineering the surface of lipid carriers with hydrophilic polymers ([@b35-ijn-2-595]; [@b36-ijn-2-595]) or coupling targeting ligands ([@b79-ijn-2-595]). Lipid nanoparticles have been coated with PEG or chitosan, in order to be able to enter the Caco-2 cell monolayers ([@b29-ijn-2-595]).

The delivery of peptides and proteins intended for therapeutic purposes might cause special difficulties regarding their encapsulation, especially because most of them have a significant hydrophobic component and thus show a tendency to adsorb onto surfaces, such as glass and plastic. Such adsorption behavior can lead to distinct losses in the amount of macromolecule available for delivery ([@b24-ijn-2-595]). Furthermore, the amount of peptide or protein to be incorporated within the system is dependent on their physicochemical properties and on the production procedure ([@b44-ijn-2-595]). The present review describes in detail the use of colloidal carriers composed of lipid materials for the delivery of peptides and proteins, particularly for oral and parenteral administration.

State of the art in peptide and protein delivery
================================================

The convenience and acceptability of the oral route for drug administration means that it has received much attention for the delivery of macromolecules, such as peptides and proteins. It has already been shown that the nanoencapsulation of biomacromolecules in colloidal particles protects them against the harsh environment of the gastrointestinal tract, and enhances their transmucosal transport ([@b62-ijn-2-595]; [@b109-ijn-2-595]). This ability of the colloidal carriers to enhance the transport of the associated macromolecules has been attributed to different mechanisms depending on the nanocarrier composition. These mechanisms are ([@b29-ijn-2-595]): (i) mucoadhesion, (ii) particle internalization phenomenon, and (iii) permeation enhancing effect. Various approaches have been used in an attempt to overcome these barriers and to increase the oral bioavailability of such bioactives including the use of polymeric particulates. The encapsulation within such particulate delivery systems can protect peptides and proteins from proteolytic enzymes. Moreover, if the size of the particles is sufficiently small (\<1 μm), they may pass across the intestinal mucosa and thus facilitate the absorption of the bioactive drugs from the gut lumen ([@b117-ijn-2-595]). Hydrophobic nanoparticles are preferentially transported through the gut associated lymphoid tissue, whereas particles with a more hydrophilic nature are transported across the regular enterocytes ([@b29-ijn-2-595]). Under such circumstances, the material used for the preparation of the particulate carrier must be biodegradable ([@b117-ijn-2-595]). Examples of biocompatible and physiological materials are the lipids used for the production of lipid-based colloidal carriers. Hydrophilic polymers such as polyacrylate derivatives and chitosan are examples of mucoadhesive materials used to coat these colloidal carriers. Regarding parenteral administration, macromolecules have been delivered by means of fat emulsions and liposomes ([@b90-ijn-2-595]). In the 60ies, the first safe parenteral fat emulsion (Intralipid^®^) was developed by Wretlind for parenteral nutrition ([@b78-ijn-2-595]; [@b68-ijn-2-595], [@b69-ijn-2-595]). This was the beginning of a new delivery system for lipophilic drugs, which can be incorporated easily into the oil droplets. Other interesting parenteral carrier systems are the liposomes. Major obstacles for the development of liposomal formulations intended for parenteral drug delivery, are the limited physical stability of the dispersions, drug leakage, low activity due to no specific tumor targeting, non specific clearance by the (MPS) and difficulties in scaling up the production procedure ([@b5-ijn-2-595]; [@b104-ijn-2-595]).

Lipid-based colloidal carriers
==============================

Liposomes
---------

Liposomes are concentric bilayered vesicles in which an aqueous volume is entirely enclosed by a membranous lipid bilayer mainly composed of natural or synthetic phospholipids. Liposomes are formed when thin lipid films or lipid cakes are hydrated and stacks of liquid crystalline bilayers become fluid and swell. During stirring, hydrated lipid sheets detach and self associate to form vesicles, which prevent interaction of water with the hydrocarbon core of the bilayer at the edges. Depending on the method of preparation, lipid vesicles can be multi-, oligo- or unilamellar, containing many, a few, or one bilayer shell(s), respectively. The diameter of the lipid vesicles may vary between about 20 nm and a few hundred micrometers ([@b116-ijn-2-595]). Small unilamellar vesicles (SUVs) are surrounded by single lipid layer (25--50 nm), whereas several lipid layers separated by intermittent aqueous layer surround large unilamellar vesicles (LUV) (100--200 μm). Giant unilamellar vesicles (GUV) have a mean diameter of 1--2 μm, multilamellar vesicles (MLV) have a mean diameter between 1 μm and 2 μm (10 layers). Multivesicular vesicles are liposomes with lots of vesicles inside. Liposomes are characterized in terms of size, surface charge and number of bilayers ([@b116-ijn-2-595]).

Enveloped viruses, such as influenza or HIV, carry fusogenic proteins on their surface by which they enter the host cell ([@b110-ijn-2-595]). Membrane destabilization and fusion is accomplished by a short amphiphilic sequence, the fusion peptide, located either at the top or in an internal region of the protein, which gets exposed upon receptor recognition or at acid pH upon endocytosis. Anchoring the peptide to the lipid bilayer via a myristic chain was shown to greatly enhance the fusogenic action and may provide a convenient way of incorporating the peptides into vesicular carriers.

An alternative, more cost-effective and less immunogenic approach relies on the adsorption of pH-titrable polymers to the liposomal surface. Poly-histidine and polylysine, for example, become positively charged upon lowering the pH and have been shown to destabilize and fuse negatively charged membranes in vitro. Polyanions, bearing carboxyl groups, are useful for destabilizing and fusing both negatively charged as well as uncharged membranes, due to their hydrophobic character at low pH. Promising pH-sensitive polyanions are, for example, poly(acrylic acid) derivatives and succinylated poly(glycerol)s. Altogether, there remains much potential to be explored with synthetic polymers and many open questions concerning their behavior in combination with liposomal carriers in vivo ([@b3-ijn-2-595]). Peptides and proteins associated to liposomes are summarized in [Table 1](#t1-ijn-2-595){ref-type="table"}.

The methods below have been used for the encapsulation of peptides and proteins in liposomes. If natural or synthetic long-tailed phospholipids are dispersed in aqueous solution they form large liposomes, ie, multilamellar vesicles (MLV). Several methods have been developed to form unilamellar vesicles from multi-bilayers ([@b95-ijn-2-595]).

In the dry lipid hydration method, the vesicle-forming amphiphiles are first dissolved in an organic solvent (often chloroform) and the solvent is completely removed by rotatory evaporation and high vacuum drying in a round bottom flask. In this way, a thin, dry lipid film is formed at the inner surface of the flask walls, to which an aqueous solution containing the peptide or protein to be entrapped is added. Vigorous shaking with the help of a vortex mixer above the phase transition temperature (*T*m) of the lipids leads to a dispersion of the lipid multi-layers in the aqueous solution, which results in the formation of a heterogeneous population of liposomes. The resulting size distribution and lamellarity of the MLV is highly heterogeneous, but sophisticated procedures have been developed to produce uniformly sized liposomes ([@b26-ijn-2-595]; [@b106-ijn-2-595]; [@b105-ijn-2-595]; [@b108-ijn-2-595]; [@b13-ijn-2-595]).

With the extrusion method, a controlled reduction in size and lamellarity of MLV can be achieved by using track-etch polycarbonate filters which contain almost cylindrical pores of a defined size. The MLV suspension is passed under moderate pressure repetitively (usually 10 times) through these filters above the *T*m which leads to a mechanical transformation of the large vesicles into smaller ones. Usually, all the extrusion is started with filters containing relatively large pores (mean diameter, eg, 400 nm), followed by a filtration through smaller pores (200 nm and often finally 100 nm) ([@b110-ijn-2-595]; [@b114-ijn-2-595]).

With the freezing and thawing method, upon repetitively freezing the MLV suspension in liquid nitrogen (at −195 °C), it is then thawed at a temperature above *T*m. The vesicle suspension may undergo certain physicochemical changes thereby often equilibrating the internal and external aqueous phases of the vesicles, resulting in an increased association efficiency and possibly leading to the formation of an increased population of multivesicular vesicles (MVV) and to an elimination by means of fusion processes of very small vesicles eventually present. Typically, freezing-thawing cycles are repeated 3 to 6 times ([@b59-ijn-2-595]; [@b55-ijn-2-595]; [@b8-ijn-2-595]).

During the sonication method, MLV are treated, for a long period, with a probe type or bath type sonicator above the *T*m under an inert atmosphere (usually nitrogen or argon) which leads to the defragmentation of MLV into small (sonicated) unilamellar vesicles (SUV) of diameters usually below 50 nm. The size of the SUV depends mainly on the sonication conditions and on the vesicle membrane composition (eg, cholesterol content).

In the dehydration-rehydration method, dehydrating preformed vesicles followed by a controlled rehydration above the *T*m leads to the fusion of small preformed vesicles, resulting in multilamellar vesicles with high association efficiency. After rehydration, the new vesicles formed are considerably larger than the initially present SUV and MLV ([@b32-ijn-2-595]).

In reverse-phase evaporation method, a water-immiscible organic solvent of low boiling point is used in which the vesicle-forming amphiphiles are soluble, eg, diethyl ether, isopropyl ether, or mixtures of these ethers with chloroform or methanol. The amphiphiles are first dissolved in the solvent, possibly with the help of chloroform or methanol if the solubility is too low. After adding the aqueous peptide or protein solution, the system is vortexed and briefly sonicated in a bath-type sonicator until a relatively stable (reverse) emulsion is formed. On the removal of solvent under reduced pressure, the reverse emulsion transforms into an aqueous vesicle dispersion, which contains a considerable amount of the originally present peptide or protein entrapped within the vesicles. The association efficiency obtained with this procedure is usually rather high ([@b121-ijn-2-595]).

In the so-called 'pro-liposome' method, an initial mixture containing vesicle-forming amphiphiles, ethanol and water, is converted into vesicles by a simple dilution step ([@b116-ijn-2-595]; [@b3-ijn-2-595]; [@b95-ijn-2-595]).

The double emulsification procedure involves the formation of a simple w/o emulsion. This first emulsion is then mixed with a second aqueous solution to form a multiple w/o/w emulsion ([@b123-ijn-2-595]; [@b56-ijn-2-595]; [@b89-ijn-2-595]; [@b23-ijn-2-595]).

Lipid nanoparticles
-------------------

### Solid lipid nanoparticles

For the location of drugs into SLN, the literature describes three different models according to [@b71-ijn-2-595] and [@b63-ijn-2-595]: (i) the homogeneous matrix model, (ii) the drug-enriched shell model, and (iii) the drug-enriched core model. The morphological differences between those models depend mainly on the composition of the formulation itself, ie, the chemical nature of the bioactive, lipid, and surfactant, as well as on the production ([@b98-ijn-2-595]). The matrix model is defined as a homogeneous lipid matrix with molecularily dispersed drug or drug being present in amorphous clusters. It is described for SLN prepared by the cold high pressure homogenization (HPH, described below) technique or when incorporating very lipophilic drugs in SLN when applying the hot HPH technique. When using the cold HPH, the bulk lipid contains the dissolved drug in molecularly dispersed form. Mechanical breaking of solid milled, drug-loaded bulk lipid by HPH leads to nanoparticles having the homogeneous matrix structure. The same will happen when the oil droplets produced by the hot HPH are cooled, crystallize, and no phase separation between lipid and drug occurs. This model is assumed for entrapped drugs that can show prolonged release from SLN ([@b71-ijn-2-595]). The drug-enriched shell model is described by an outer shell enriched with drug, which covers a lipid core. This model is obtained when phase separation occurs during the cooling process from the liquid oil droplet to the formation of SLN when applying the hot HPH. The lipid precipitates first forming an almost drug-free lipid core. At the same time, the concentration of active compound in the remaining liquid lipid increases continuously. Finally, the compound-enriched shell crystallizes. Once the drug molecules are enriched in the outer shell of the particles, this model is assumed for drugs that release very fast from SLN. The drug-enriched core model is formed when the opposite mechanism as described for the former model occurs. In this case, the drug precipitates first and the lipid shell formed around this core will have distinctly less drug. This leads to a membrane-controlled release governed by Fick's law of diffusion ([@b74-ijn-2-595]). This model is formed when the drug concentration is close to its saturation solubility in the melted lipid. It has been reported that drugs can also be linked with the outer layer of SLN composed of phospholipids and steric stabilizers. Distribution of the drug depends both on its physicochemical characteristics and on the components of the SLN. It is, however, most influenced by the partition coefficient of the drug molecules ([@b16-ijn-2-595]; [@b99-ijn-2-595]). Examples of peptides and proteins associated to SLN are summarized in [Table 2](#t2-ijn-2-595){ref-type="table"}.

The literature describes four main methods for the incorporation of peptides and proteins into SLN. The HPH can be performed at elevated temperature (hot HPH technique) or at or below room temperature (cold HPH technique) ([@b125-ijn-2-595]; [@b27-ijn-2-595]; [@b64-ijn-2-595]; [@b74-ijn-2-595], [@b75-ijn-2-595]). The particle size is decreased by cavitation and turbulences. For the hot HPH, the lipid is heated at approx. 5--10ºC above its melting point, and further added the bioactive to this melted lipid phase. This mixture is then combined with an aqueous surfactant solution heated at the same temperature. A hot pre-emulsion is formed by high speed stirring. This hot pre-emulsion is converted into a nanoemulsion when processed in a temperature controlled high pressure homogenizer, generally applying between 3 to 5 cycles at 500 bar. The obtained nanoemulsion recrystallizes upon cooling down to room temperature forming SLN ([@b15-ijn-2-595]). The cold HPH is a suitable technique for processing temperature labile drugs or hydrophilic drugs. Here, the lipid and drug are melted together and then rapidly ground under liquid nitrogen forming solid lipid microparticles. A pre-suspension is formed by high speed stirring of the particles in a cold aqueous surfactant solution. This pre-suspension is then homogenized at or below room temperature forming SLN, the homogenizing conditions are generally 5 cycles at 500 to 800 bar ([@b1-ijn-2-595]).

In the solvent diffusion method, the lipid is first dissolved in an organic phase, such as ethanol and acetone, using a water bath at 50 ºC. An acidic aqueous phase is required in order to adjust the zeta potential to induce lipid coacervation, which leads to formation of SLN. The particles are then easily separated by centrifugation ([@b45-ijn-2-595]).

In the w/o/w double emulsion method, the hydrophilic drug is encapsulated, along with a stabilizer to prevent drug partitioning to the external water phase during solvent evaporation, in the internal water phase of a w/o/w double emulsion ([@b31-ijn-2-595]; [@b29-ijn-2-595]; [@b29-ijn-2-595]; [@b111-ijn-2-595]; [@b126-ijn-2-595]).

The group of Gasco has developed and optimized a suitable method for the preparation of SLN via microemulsions, which has been adapted and/or modified by different labs ([@b94-ijn-2-595]; [@b27-ijn-2-595]; [@b43-ijn-2-595]; [@b46-ijn-2-595]). Firstly, a warm microemulsion is prepared by stirring, containing typically 10% of melted solid lipid, 15% of surfactant and up to 10% of co-surfactant. This warm microemulsion is then dispersed under stirring in excess cold water at approx. 2 to 3 ºC (typical ratio 1:50) using an especially developed thermostated syringe. The excess of water is removed either by ultra-filtration or by lyophilization in order to increase the particle concentration ([@b119-ijn-2-595]; [@b87-ijn-2-595]).

### Nanostructured lipid carriers

As mentioned before, the main difference between SLN and NLC is the fact the concept of the latter is performed by nanostructuring the lipid matrix, to increase the drug loading and to prevent drug expulsion. This could be realized in three ways: (i) the imperfect type, (ii) the multiple type, and (iii) the amorphous type.

Spatially different lipids, eg, acylglycerols composed of different fatty acids are mixed. Using spatially different lipids leads to larger distances between the fatty acid chains of the acylglycerols and general imperfections in the crystal and thus to more room for the accommodation of the drugs. The highest drug load could be achieved by mixing solid lipids with small amounts of liquid lipids. This model is called the imperfect type.

If higher amounts of oil are mixed with the solid lipid, a different type of nanostructure is present. Here, the solubility of the oil molecules in the solid lipid is exceeded; this leads to phase separation and the formation of oily nanocompartments within the solid lipid matrix ([@b49-ijn-2-595]; [@b49-ijn-2-595]; [@b48-ijn-2-595]). Many drugs show a higher solubility in oils than in solid lipids so that they can be dissolved in the oil and still be protected from degradation by the surrounding solid lipids. This type of NLC is called the multiple type, and can be regarded as an analogue to w/o/w emulsions since it is an oil-in-solid lipid-in-water dispersion.

Since drug expulsion is caused by ongoing crystallization or transformation of the solid lipid, this can be minimized by the formation of a third type, the amorphous type. Here, the particles are solid but crystallization upon cooling is avoided by mixing special lipids (eg, hydroxyoctacosanylhydroxy-stearate and isopropylmyristate) ([@b49-ijn-2-595]; [@b49-ijn-2-595]; [@b119-ijn-2-595]).

The methods used to produce NLC for peptide and protein are the above described w/o/w double emulsion, and the hot HPH technique. Examples of bioactives associated to NLC for oral delivery are the calcitonin and cyclosporine A. NLC for the delivery of calcitonin have been produced by w/o/w double emulsion, resulting an association efficiency higher than 90% ([@b29-ijn-2-595]; [@b29-ijn-2-595]). NLC with cyclosporine A have been produced by hot HPH ([@b74-ijn-2-595]).

Toxicological concerns
======================

One can anticipate that lipid-based colloidal carriers are well tolerated in living systems because they are made of physiological compounds and therefore, metabolic pathways exist decreasing the risk of acute and chronic toxicity. Of course, the toxicity of the emulsifiers has to be considered ([@b63-ijn-2-595]).

Lipid carriers prepared with several lipids and emulsifying agents did not exhibit any cytotoxic effects in vitro up to concentrations of 2.5% lipid ([@b79-ijn-2-595]). In fact, it has been shown that even concentrations higher than 10% of lipid phase led to a viability of 80% with human granulocytes in culture ([@b72-ijn-2-595]). For comparison, PLA nanoparticles showed complete cell death at 0.5%. The low toxicity of lipid nanoparticles has already been shown in human promyelotic cells (HL60) ([@b29-ijn-2-595]; [@b79-ijn-2-595]).

It can be assumed that the cytotoxicity of the SLN can be mainly attributed to components of the aqueous phase, especially to non-ionic emulsifiers and preservatives that have eventually been used ([@b93-ijn-2-595]).

Considering a future application of these systems for peptide or protein delivery, for most biomacromolecules a parenteral application is inevitable. For that reason, the cytotoxicity of liposomes and lipid nanoparticles is an essential product parameter with regard to a prospective in vivo tolerance evaluation in humans and/or animals. Most studies have been conducted with acylglycerols composed of fatty acids and lecithins, which are mostly accepted as safe. Good tolerability depends in the first line on the used surfactant and secondarily on the lipid. To formulate parental lipid-based carriers, surfactant of GRAS status must be employed, eg, lecithin, Tween 80, Poloxamer 188, Span 85, and sodium glycocholate. When performing bolus injections into mice good tolerability was found for most of these surfactants coating SLN ([@b119-ijn-2-595]). As described, for cetyl palmitate SLN with different surfactants no acute toxicity and no increase in liver and spleen weight was observed. After autopsy and histopathology no significant evidence was documented that SLN were acute toxic to tested animals ([@b119-ijn-2-595]).

No problems should be observed for peroral or trans-dermal administration and intramuscular or subcutaneous injection if appropriate surfactants are used. The particle size is not a very critical issue for these administration routes, because a low content of microparticles might decrease the performance of the colloidal system, but will not cause toxic events. Size is relevant if such formulations are intended for intravenous administration. In this case toxicological problems may arise if size is not controlled. Injections of highly polydispersed particle dispersions can cause embolism due to the risk of particle aggregation during injection. When particle dispersions are intended for intravenous administration production of monodispersed formulations must be guaranteed. Moreover, colloidal carriers can be coated with hidrophilic polymers or albumin to actively target the incorporated drugs to specific cells, tumors and/or organs. This strategy can be successfully applied to concentrate drugs in such target tissues minimizing systemic side effects and therefore toxicity. The absence of pyrogens must be checked for parenteral administration. Problems may arise, because colloidal carriers may interfere with the pyrogens causing gelation of the suspension, which could result in embolism.

Conclusions
===========

In the future we can expect an increasing number of therapeutic molecules such as proteins, oligonucleotides and DNA as vaccine or as drug for gene therapy. The employment of lipid-based carriers has been found to be suitable for the administration of peptides and proteins through different routes.

Liposomes have been used successfully in the field of biology, biochemistry and medicine since its origin ([@b10-ijn-2-595]). It exhibits a number of advantages in terms of amphiphilic character. Biocompatibility, and ease of surface modification rendering it a suitable candidate delivery system for peptides and proteins molecules.

Once lipid nanoparticles are a new and innovative therapeutic delivery system, we can expect in the future an increasing number of contributions describing delivery of recombinant proteins ([@b119-ijn-2-595]). Lipid nanoparticles, particularly, NLC are a promising approach for the formulation of peptides and proteins with poor aqueous solubility. Since nearly 40% of the new drug compounds are hydrophobic, it appears that more drug products will be formulated as NLC for the pharmaceutical market in the very near future.

###### 

Examples of peptides and proteins associated to liposomes, the production procedure and the association efficiency

  **Protein/peptide**                                    **Production procedure**        **Association efficiency (%)**   **References**
  ------------------------------------------------------ ------------------------------- -------------------------------- ---------------------------------------------------------------------------
  Adamantyltripeptides                                   Dry lipid hydration             \-                               ([@b26-ijn-2-595])
  Anti-ovalbumin antibodies                              Dry lipid hydration             \-                               ([@b13-ijn-2-595])
  Basic fibroblaste growth factor                        Freeze-thawing extrusion        75--80                           ([@b88-ijn-2-595]; [@b59-ijn-2-595])
  Bovine serum albumin                                   Reversal evaporation            25--71                           ([@b22-ijn-2-595], [@b23-ijn-2-595]; [@b82-ijn-2-595])
                                                         Double emulsification           43--71                           
                                                         Freeze-thawing                  20--45                           
  Calcitonin                                             Dry lipid hydration             20                               ([@b106-ijn-2-595], [@b105-ijn-2-595]; [@b108-ijn-2-595])
  Enkephalin                                             Double emulsification           50--85                           ([@b123-ijn-2-595])
  Epidermal growth factor receptor                       Freeze-thawing extrusion        20--30                           ([@b55-ijn-2-595])
  Haptides                                               \-                              ∼100                             ([@b37-ijn-2-595])
  Hemoglobin                                             Dry lipid hydration extrusion   37--62                           ([@b4-ijn-2-595]; [@b86-ijn-2-595]; [@b107-ijn-2-595]; [@b120-ijn-2-595])
  Horseadish peroxidase                                  Extrusion                       2--5                             ([@b114-ijn-2-595])
  Human gamma-globulin                                   Dehydration-rehydration         30--31                           ([@b32-ijn-2-595])
  Insulin                                                Reverse phase evaporation       30--82                           ([@b127-ijn-2-595]; [@b38-ijn-2-595])
                                                         Freezing-thawing                                                 
  Leishmania antigen                                     Freeze-thawing extrusion        \-                               ([@b8-ijn-2-595])
  Leridistim                                             Double emulsification           \>70                             ([@b56-ijn-2-595])
  Leuprolide                                             Dry lipid hydration             37--76                           ([@b41-ijn-2-595];
                                                         Reverse phase evaporation       33--72                           [@b5-ijn-2-595]; [@b97-ijn-2-595]; [@b14-ijn-2-595])
  Nerve growth factor                                    Reverse phase evaporation       24--34                           ([@b121-ijn-2-595])
  Octreotide                                             Double emulsification           50--85                           ([@b123-ijn-2-595])
  Progenipoietin                                         Double emulsification           80--90                           ([@b89-ijn-2-595])
  Recombinant malaria protein antigens                   \-                              \-                               ([@b2-ijn-2-595])
  Superoxide dismutase                                   Dry lipid hydration             1--13                            ([@b92-ijn-2-595])
                                                         Dehydration-rehydration         2--3                             
                                                         Pro-liposome                    39--65                           
  TAT[a](#tfn1-ijn-2-595){ref-type="table-fn"} peptide   Extrusion                       \-                               ([@b110-ijn-2-595])

*Trans*activating transcriptional activator.

###### 

Examples of peptides and proteins associated to SLN, the production procedure and the association efficiency

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Protein/peptide**                                              **Production procedure**                                      **Association efficiency (%)**   **References**
  ---------------------------------------------------------------- ------------------------------------------------------------- -------------------------------- ----------------------------------------------------------
  Bovine serum albumin                                             Hot HPH[a](#tfn2-ijn-2-595){ref-type="table-fn"} technique\   ∼100                             ([@b40-ijn-2-595]; [@b93-ijn-2-595]; [@b87-ijn-2-595])
                                                                   Microemulsion technique                                                                        

  Calcitonin                                                       w/o/w double emulsion                                         75--90                           ([@b29-ijn-2-595]; [@b29-ijn-2-595])

  Cyclosporine A                                                   Microemulsion technique\                                      6.0--13 96                       ([@b74-ijn-2-595], [@b77-ijn-2-595]; [@b113-ijn-2-595])
                                                                   Hot HPH technique                                                                              

  Gonadorelin                                                      Solvent diffusion                                             50--69                           ([@b44-ijn-2-595])

  Human recombinant EPG[b](#tfn3-ijn-2-595){ref-type="table-fn"}   Microemulsion technique                                       \-                               ([@b87-ijn-2-595])

  Insulin                                                          w/o/w double emulsion                                         27--68 35--45                    ([@b31-ijn-2-595]; [@b111-ijn-2-595]; [@b126-ijn-2-595])

  Lysozime                                                         Cold HPH technique                                            ∼100                             ([@b1-ijn-2-595])

  Streptavidin                                                     Microemulsion technique                                       ∼100                             ([@b87-ijn-2-595])

  TAT[c](#tfn4-ijn-2-595){ref-type="table-fn"} peptide             Hot HPH technique                                             \-                               ([@b15-ijn-2-595])

  Thymopentin                                                      Microemulsion technique                                       2--5                             ([@b65-ijn-2-595])
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

High Pressure Homogenization;

Epidermal Growth Factor;

*Trans*activating Transcriptional Activator.
